Psychiatr. pro Praxi, 2004; 5: 245-249

Compliance v léčbě schizofrenie

MUDr. Luboš Janů Ph.D, MUDr. Sylva Racková
Psychiatrická klinika FN a LF UK v Plzni

Keywords: compliance, schizophrenia, antipsychotics, adherence, relaps.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janů L, Racková S. Compliance v léčbě schizofrenie. Psychiatr. praxi. 2004;9(5):245-249.

Compliance je zásadním faktorem pro dlouhodobou léčbu schizofrenie. Zhruba 50?% schizofreniků je noncompliantních, což vede často k rehospitalizaci. Důvody jsou rozličné. Významný je náhled onemocnění a přijetí medikace. Vedlejší účinky, zejména subjektivně nepříjemné, jsou častým důvodem přerušení medikace. Novější antipsychotika nejsou nežádoucích účinků prosta. V textu jsou zmiňovány možnosti edukačních programů, minimalizace nežádoucích účinků, vliv choroby a charakteristik pacientů.

Compliance in the Treatment of Schizophrenia

Compliance is a principal factor in the long-therm treatment of schizophrenia. About 50% of schizophrenics are noncompliant. Noncompliance with antipsychotic medication leads to rehospitalization. The reasons for being noncompliant are different. Insight of schizophrenia and acceptance of medication are important. Adverse events, subjectively unpleasant, are often reason for antipsychotic discontinuation. Novel antipsychotics are not clear of adverse events. Educational multiapproach programs, minimalisation of adverse events possibilities, influence of the illness and patients characteristics are discussed.

Download citation

References

  1. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand Suppl. 1994; 380: 27-32. Go to original source... Go to PubMed...
  2. Boyer CA, McAlpine DD, Pottick KJ, Olfson M.: Identifying risk factors and key strategies in linkage to outpatient psychiatric care. Am J Psychiatry. 2000 Oct; 157 (10): 1592-1598. Go to original source... Go to PubMed...
  3. Caton CL, Koh SP, Fleiss JL, Barrow S, Goldstein JM.: Rehospitalization in chronic schizophrenia. J Nerv Ment Dis. 1985 Mar; 173 (3): 139-148. Go to original source... Go to PubMed...
  4. Collins AA, Remington GJ, Coulter K, Birkett K.: Insight, neurocognitive function and symptom clusters in chronic schizophrenia. Schizophr Res. 1997 Oct 17; 27 (1): 37-44. Go to original source... Go to PubMed...
  5. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry. 1990 Nov; 41 (11): 1203-1211. Go to original source... Go to PubMed...
  6. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998 Aug; 49 (8): 1095. Go to original source... Go to PubMed...
  7. Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology. 2003 Jan; 28 (Suppl 1): 69-82. Go to original source... Go to PubMed...
  8. Davies A, Adena MA, Keks NA, Catts SV, Lambert T, Schweitzer I. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther. 1998 Jan-Feb; 20 (1): 58-71. Go to original source... Go to PubMed...
  9. Dolder CR, Lacro JP, Leckband S, Jeste DV. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol. 2003 Aug; 23 (4): 389-399. Go to original source... Go to PubMed...
  10. O'Donnell C, Donohoe G, Sharkey L, Owens N, Migone M, Harries R, Kinsella A, Larkin C, O'Callaghan E. Compliance therapy: a randomised controlled trial in schizophrenia. BMJ. 2003 Oct 11; 327 (7419): 834. Go to original source... Go to PubMed...
  11. Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl. 1994; 382: 11. Go to original source... Go to PubMed...
  12. Gerlach J, Larsen EB. Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr Scand Suppl. 1999; 395: 113-117. Go to original source... Go to PubMed...
  13. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV: Adherence to treatment with antipsychotic medication and health care cost among medicaid beneficiaires with schizophrenia. Am J Psych 2004; 161, 4: 692-699. Go to original source... Go to PubMed...
  14. McGlashan TH, Carpenter WT Jr. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry. 1976 Feb; 33 (2): 231-239. Go to original source... Go to PubMed...
  15. Green JH. Frequent rehospitalization and noncompliance with treatnment. J Hosp Commun Psychiatry 1988; 39: 963-969. Go to original source...
  16. Kane JM, Borenstein M. Compliance in the long-term treatment of schizophrenia. Psychopharmacol Bull. 1985; 21(1): 23-27. Go to PubMed...
  17. Kissling W, Leucht S. Results of treatment of schizophrenia: is the glass half full or half empty? Int Clin Psychopharmacol. 1999 Jun; 14 (Suppl 3): S11-S14. Go to original source... Go to PubMed...
  18. Lieberman JA. Dopamine partial agonists. A new class of antipsychotic. CNS Drugs 2004; 18 (4): 251-267. Go to original source... Go to PubMed...
  19. Lysaker PH, Bryson GJ, Lancaster RS, Evans JD, Bell MD. Insight in schizophrenia: associations with executive function and coping style. Schizophr Res. 2003 Jan 1; 59 (1): 41-47. Go to original source... Go to PubMed...
  20. Mutsatsa SH, Joyce EM, Hutton SB, Webb E, Gibbins H, Paul S, Barnes TR. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand. 2003 Dec; 108 (6): 439-446. Go to original source... Go to PubMed...
  21. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002 Dec; 63 (12): 1121-1128. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.